Download Files:
DR2313
$28 – $450
Products Details
Product Description
– DR2313 is a potent, selective, competitive and brain-penetrant inhibitor of poly(ADP-ribose) polymerase (PARP), with IC50s of 0.20 μM and 0.24 μM for PARP-1 and PARP-2, respectively. DR2313 exhibits neuroprotective effects on ischemic injuries in vitro and in vivo[1][2].
Web ID
– HY-105692
Storage Temperature
– 4°C (Powder, protect from light)
Shipping
– Room Temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C8H10N2OS
References
– [1]Nakajima H, et, al. A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats. J Pharmacol Exp Ther. 2005 Feb;312(2):472-81.|[2]Xu Z, et, al. Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia. Am J Physiol Regul Integr Comp Physiol. 2010 Jul;299(1):R215-21.
CAS Number
– 284028-90-6
Molecular Weight
– 182.24
Compound Purity
– 98.70
SMILES
– O=C1C(CSCC2)=C2NC(C)=N1
Clinical Information
– No Development Reported
Research Area
– Neurological Disease
Solubility
– DMSO : 12.5 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL
Target
– PARP
Isoform
– PARP1;PARP2
Pathway
– Cell Cycle/DNA Damage;Epigenetics
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
